- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Astec LifeSciences Limited — Important, 08-07-2026: Updates
08-07-2026 | 08:19 pm
08-07-2026 | 08:19 pm
Astec LifeSciences achieved FY26 EBITDA break-even, with ₹453.22 Cr income and reduced losses to ₹(80.88) Cr. Gross margin improved to 33.4%. CDMO revenue was ₹235 Cr. A ₹249.35 Cr Rights Issue strengthened capital. Company invests in R&D; Labour Code changes impacted P&L.
No comments yet. Be the first to comment!